Outcome of Patients With Early Stage Hodgkin Lymphoma According to GHSG and NC1C-CTG Risk Classification: The Princess Margaret Hospital Experience

摘要

Early stage HL has an excellent prognosis, with consistent reports of OS greater than 90% in large trials of combined modality therapy. With these outcomes, a major focus of modern therapeutic approaches is to minimize the morbidity and mortality associated with treatment. That was the goal of the GHSG HD10 trial, which recendy established a new standard of care.1 Patients with favorable disease demonstrated non-inferior outcomes with respect to disease control and decreased toxicities with the delivery of less dose-intensive regimens. However, the ability to minimize the tojdcity related to treatment while simultaneously maintaining excellent outcomes and disease control is contingent upon accurately identifying those patients who are at risk for treatment failure.